MedX Health Corp. (TSX-V:MDX) has revealed that it is bringing its leading-edge DermSecure Screening Platform to Turkey.
The company said it has entered into a memorandum of understanding with Makromed/Arhan Global A.Ş for a distribution agreement that will facilitate a clinical trial of the technology at three university hospitals across Turkey in early 2022.
Pending the successful completion of the agreement’s pilot phase, MedX said its platform will become more widely available across the country.
READ: MedX Health announces appointment of Lesley Bourget as chief financial officer
The distribution agreement is the latest in a series of European commercialization pilots recently launched as part of MedX’s global commercialization strategy, building on pilots currently underway in The Netherlands and Italy. Additional commercialization pilots are anticipated in the coming months.
“I founded Makromed on the principle of the Hippocratic Oath (“first do no harm”) – for our team, the well-being of our patients is of primary importance,” said Dr. Hasan Silav, CEO of Makromed/Arhan, in a statement.
“We are confident that bringing MedX’s world-class teledermatology platform to this market will greatly improve outcomes for those dermatology patients seeking high-quality, virtual services. We look forward to working with MedX to increase this platform’s availability to patients across Turkey.”
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s DermSecure Screening Platform features high-resolution image capture technology for moles, lesions, and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
MedX’s leading telemedicine platform allows healthcare practitioners to quickly and accurately assess suspicious moles, lesions, and other skin conditions via its image capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process.
MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2 millimeters below the skin’s surface.
“We look forward to partnering with Makromed to introduce our platform to the Turkish market,” said MedX CEO Sylvain Desjeans. “This agreement builds on MedX’s commercial growth in Europe and is key to expanding our footprint around the globe, improving patient outcomes, and potentially saving more lives.”
Naman Demaghlatrous, MedX’s managing director of Europe, Middle East, and Africa, added: “With Makromed being one of the largest medical device distributors in the Turkish market, this agreement is a significant opportunity to rapidly grow MedX’s presence, providing greater access to our technology at a time when skincare patients need a virtual service like this the most.”
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham